[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620176":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":29,"locations":39,"responsibleParty":52,"collaborators":54,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":26,"enrollmentInfo":67,"targetDuration":26,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":81,"whyStopped":26,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"National Taiwan University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"LIDOCAINE","EXPERIMENTAL","Lidocaine 1 mg\u002Fkg",[13],"Drug: lidocaine",{"label":15,"type":16,"description":17,"interventionNames":18},"Saline","ACTIVE_COMPARATOR","Saline 3\\~5ml",[19],"Drug: Saline",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","lidocaine","baseline SaO2, heart rate, and systolic and diastolic blood pressure will be recorded before and every 10 minutes after drug injection",[9],null,{"type":22,"name":15,"description":24,"armGroupLabels":28,"otherNames":26},[15],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":26,"email":34},"Chih-Chieh Yu, MD.PhD","CONTACT","0972652038","sweetchieh@gmail.com",{"name":36,"role":32,"phone":37,"phoneExt":26,"email":38},"HSIAO-HAN HUANG","0932917553","clrhuang8853@gmail.com",[40],{"facility":41,"status":26,"city":42,"state":26,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":26},"National Taiwan University Hospita","Taipei","100","Taiwan","TW",{"type":47,"coordinates":48},"Point",[49,50],121.52639,25.05306,{"lat":50,"lon":49},{"type":53,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[55],{"name":56,"class":57},"Johnson & Johnson","INDUSTRY","100620176","phase-4-workflow-optimization-during-pulse-field-ablation-for-atrial-fibrillation-100620176",false,"NCT07354217","Workflow Optimization During Pulse Field Ablation for Atrial Fibrillation","PFA_workflow","Inclusion Criteria:\n\n1. Patients with paroxysmal or persistent AF and are scheduled to undergo PVI.\n2. Patients who can understand the study aims and protocol and are willing to follow the protocol for one year.\n\nExclusion Criteria:\n\n1. Informed consent could not be obtained\n2. Known allergy to study drug lidocaine.\n3. Presence of thrombus in the LA or LA appendage\n4. Underlying significant pulmonary disease, such as asthma or COPD needing long term maintenance therapy or documented interstitial lung disease","ALL","18 Years",{"count":68,"type":69},60,"ESTIMATED","INTERVENTIONAL",[72],"PHASE4","To evaluate the efficacy and safety of intravenous lidocaine in reducing diaphragmatic contraction and suppressing the cough reflex during pulsed field ablation procedures.",[75,76],"Pulsed Field Ablation","Lidocaine",[78,9,79,80],"Pulmonary Vein Isolation","Pulse Field Ablation","cough suppression","NOT_YET_RECRUITING","2026-04-16",{"date":84,"type":85},"2026-04-20","ACTUAL",{"date":87,"type":69},"2026-06-01",{"date":89,"type":69},"2030-12-31",{"name":5,"class":6},1]